Taylor 2005.

Methods	randomized controlled trial, placebo‐controlled
Participants	n = 391, non‐myeloid hematological malignancies, breast, lung, gastrointestinal, genitourinary, gynecological, other cancer (stage I‐IV); concomitant treatment: chemotherapy
Interventions	drug = Darbepoetin alpha dose = 300 µg sc Q3W hb‐target = 12‐13 g/dL planned ESA duration = 15 weeks
Outcomes	Primary: transfusion; secondary: Hb target achieved, number of transfusions, safety, QoL
Notes	study number = 37476
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Unclear risk	no description
Allocation concealment?	Low risk	central randomization